Oxion Biologics

Oxion Biologics is a private, pre-revenue biotech advancing OX118, an Fc-optimized monoclonal antibody targeting OX40L, through clinical development for a broad range of autoimmune conditions. With a first-in-human trial scheduled for Q2 2025 and a granted EU Clinical Trial Application, the company is rapidly progressing towards clinical validation. Its approach aims for true disease modification by selectively depleting pro-inflammatory cells and promoting regulatory T-cell function, targeting a multi-billion dollar market with significant unmet needs.

Fc-optimized monoclonal antibodies targeting the OX40/OX40L co-stimulatory pathway to selectively deplete pro-inflammatory antigen-presenting cells and promote regulatory T-cell function.

OX118 competes in the crowded autoimmune space against broad immunosuppressants, cytokine inhibitors (anti-TNF, anti-IL), and other co-stimulatory pathway modulators. It aims to differentiate through its precise mechanism of depleting pro-inflammatory APCs while inducing Tregs, claiming superior preclinical efficacy. Success hinges on demonstrating a better efficacy/safety profile than established and emerging therapies.